3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1/2
5
Phase 3
4
Phase 1
2
Phase NA
1
Status
Recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Other hematologic neoplasm
3
Head & Neck
1
Conditions
Leukemia, Promyelocytic, Acute
3
Leukemia
2
Oropharyngeal Neoplasms
1
Neoplasms
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
221
Carboplatin
214
Cisplatin
202
Paclitaxel
181
Gemcitabine
148
Docetaxel
126
Capecitabine
113
Cyclophosphamide
101
Pemetrexed
100
Dexamethasone
100
Specimen Handling
98
Oxaliplatin
96
Magnetic Resonance Spectroscopy
96
Radiotherapy
92
Doxorubicin
91
Fluorouracil
88
Bevacizumab
84
Leucovorin
73
Nivolumab
72
Rituximab
71
Vincristine
67
durvalumab
65
Lenalidomide
64
atezolizumab
61
Radiation
61
Irinotecan
61
Etoposide
60
130-nm albumin-bound paclitaxel
58
Prednisone
55
Letrozole
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 3
×
Tretinoin
×
1 year
×
Clear all
NCT02688140
2026-05-29
TUD-APOLLO-064
Technische Universität Dresden
Phase 3
Completed
133 enrolled
NCT06706401
2026-04-24
LYSARI
Centre Leon Berard
Phase 3
Recruiting
460 enrolled
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled
NCT07296445
2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3
Not yet recruiting
120 enrolled